Teachers Advisors LLC Acquires 126,250 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Teachers Advisors LLC boosted its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 20.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 744,107 shares of the biopharmaceutical company’s stock after buying an additional 126,250 shares during the quarter. Teachers Advisors LLC owned approximately 0.34% of Alexion Pharmaceuticals worth $88,988,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Ameriprise Financial Inc. lifted its stake in Alexion Pharmaceuticals by 3.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after buying an additional 215,005 shares in the last quarter. Clearbridge Investments LLC lifted its stake in Alexion Pharmaceuticals by 9.5% in the 4th quarter. Clearbridge Investments LLC now owns 3,541,871 shares of the biopharmaceutical company’s stock valued at $423,572,000 after buying an additional 307,117 shares in the last quarter. Franklin Resources Inc. lifted its stake in Alexion Pharmaceuticals by 10.4% in the 4th quarter. Franklin Resources Inc. now owns 2,583,710 shares of the biopharmaceutical company’s stock valued at $308,986,000 after buying an additional 243,650 shares in the last quarter. Geode Capital Management LLC lifted its stake in Alexion Pharmaceuticals by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,256,415 shares of the biopharmaceutical company’s stock valued at $269,251,000 after buying an additional 62,266 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its stake in Alexion Pharmaceuticals by 10.3% in the 4th quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock valued at $223,818,000 after buying an additional 174,606 shares in the last quarter. 95.36% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

In related news, EVP Julie O’neill sold 1,625 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $119.83, for a total value of $194,723.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ludwig Hantson sold 13,245 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total transaction of $1,540,525.95. Following the completion of the sale, the chief executive officer now owns 131,425 shares of the company’s stock, valued at approximately $15,286,041.75. The disclosure for this sale can be found here. Insiders sold a total of 28,700 shares of company stock valued at $3,345,708 in the last quarter. 4.35% of the stock is owned by insiders.

Shares of NASDAQ ALXN opened at $109.24 on Friday. The company has a market cap of $24,795.18, a PE ratio of 21.17, a PEG ratio of 1.03 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. Alexion Pharmaceuticals, Inc. has a 1 year low of $96.18 and a 1 year high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business had revenue of $909.70 million during the quarter, compared to the consensus estimate of $880.38 million. During the same quarter last year, the firm earned $1.26 EPS. The business’s revenue was up 9.5% compared to the same quarter last year. sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 6.12 EPS for the current fiscal year.

A number of research analysts recently weighed in on the stock. Evercore ISI raised shares of Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research note on Monday, February 5th. Citigroup decreased their price target on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating on the stock in a research note on Friday, February 9th. Nomura increased their price objective on shares of Alexion Pharmaceuticals from $148.00 to $156.00 and gave the company a “buy” rating in a report on Thursday, March 15th. BMO Capital Markets increased their price objective on shares of Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a report on Friday, February 9th. Finally, Leerink Swann cut their price objective on shares of Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating for the company in a report on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and twenty have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average price target of $155.55.

WARNING: This article was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/teachers-advisors-llc-grows-position-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply